Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Wallace, T. et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J. Cancer 5, 3 (2014).
Litwin, M. S. & Tan, H.-J. The diagnosis and treatment of prostate cancer: a review. JAMA 317, 2532–2542 (2017).
Burgess, L., Roy, S., Morgan, S. & Malone, S. A review on the current treatment paradigm in high-risk prostate cancer. Cancers 13, 4257 (2021).
Desai, K., McManus, J. M. & Sharifi, N. Hormonal therapy for prostate cancer. Endocr. Rev. 42, 354–373 (2021).
Aggarwal, R. et al. Prognosis associated with luminal and basal subtypes of metastatic prostate cancer. JAMA Oncol. 7, 1644–1652 (2021).
Wang, Z. et al. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. Prostate 81, 1191–1201 (2021).
Dorff, T. B. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636–1644 (2024).
Dolgin, E. Personalized cancer vaccines pass first major clinical test. Nat. Rev. Drug Discov. 22, 607–609 (2023).
Kalantari, E. et al. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Int. J. Exp. Pathol. 100, 123–132 (2019).
Mohsenzadegan, M. et al. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immunol. Immunother. 62, 1609–1618 (2013).
Taeb, J., Asgari, M., Abolhasani, M., Farajollahi, M. M. & Madjd, Z. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients. Pathol. Res Pract. 210, 18–23 (2014).
Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target. Ther. 6, 362 (2021).
Yang, D., Liu, J., Qian, H. & Zhuang, Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322–1332 (2023).
Hammerstrom, A. E., Cauley, D. H., Atkinson, B. J. & Sharma, P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 31, 813–828 (2011).
Lin, X. et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol. Cancer 23, 108 (2024).
Khalaji, A. et al. Don’t eat me/eat me signals as a novel strategy in cancer immunotherapy. Heliyon 9, e20507 (2023).
El-Tanani, M. et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies. Cancer Lett. 591, 216894 (2024).
Vafaei, S. et al. Increased expression of PDGFA and RAF1 in Tumor-derived exosomes in human colorectal cancer. Cell. Mol. Biol. 71, 1–13 (2025).
Claessens, F. et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal. 6, e008 (2008).
Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra67 (2014).
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
Burger, J. A., Stewart, D. J., Wald, O. & Peled, A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev. Anticancer Ther. 11, 621–630 (2011).
Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Dev. Ther. 9, 4479–4499 (2015).
He, J. et al. Immunotherapy vaccines for prostate cancer treatment. Cancer Med. 13, e70294 (2024).
Rastogi, I., Muralidhar, A. & McNeel, D. G. Vaccines as treatments for prostate cancer. Nat. Rev. Urol. 20, 544–559 (2023).
Miyahira, A. K. et al. Beyond seed and soil: understanding and targeting metastatic prostate cancer; report from the 2016 Coffey–Holden Prostate Cancer Academy Meeting. Prostate 77, 123–144 (2017).
Dhar, R. et al. Cancer immunotherapy: recent advances and challenges. J. Cancer Res. Ther. 17, 834–844 (2021).
Ghemrawi, R. et al. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicines 12, 2158 (2024).
Raghani, N. R. et al. Revolutionizing cancer treatment: Comprehensive insights into immunotherapeutic strategies. Med. Oncol. 41, 51 (2024).
Mitra, A., Kumar, A., Amdare, N. P. & Pathak, R. Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion. Biology 13, 307 (2024).
Liu, D., Che, X., Wang, X., Ma, C. & Wu, G. Tumor vaccines: unleashing the power of the immune system to fight cancer. Pharmaceuticals 16, 1384 (2023).
Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).
Hall, M. S. et al. Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer 11,10 (2023).
Kaczmarek, M. et al. Cancer vaccine therapeutics: limitations and effectiveness—a literature review. Cells 12, 2159 (2023).
Liang, J. & Zhao, X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol. Med. 18, 352–371 (2021).
Bouchelouche, K. et al. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin. Nuclear Med. 41, 29-44 (2011).
Ghods, R. et al. High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Cancer Immunol. Immunother. 63, 1319–1327 (2014).
Henríquez I. et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines 9, 9 (2021).
Vafaei, S. et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 22, 2 (2022).
Wang, Y., Wang, M., Wu, H. X. & Xu, R. H. Advancing to the era of cancer immunotherapy. Cancer Commun. 41, 803–829 (2021).
Schepisi, G. et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer. 7, 1–11 (2019).
Wolf, P., Alzubi, J., Gratzke, C. & Cathomen, T. J. N. R. U. The potential of CAR T cell therapy for prostate cancer. Nat Rev Urol. 18, 556–571 (2021).
Gorchakov, A. A., Kulemzin, S. V., Kochneva, G. V. & Taranin A. V. J. E. U. Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer. Eur Urol. 77, 299–308 (2020).
Zhou, H.-M., Zhang, J.-G., Zhang, X. & Li, Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct. Target. Ther. 6, 62 (2021).
Vafaei, S. et al. Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review. Cancer Manag. Res. 11, 8669–8698 (2019).
Qin, S. et al. A precision-engineered dendritic cell-targeted mRNA nanovaccine for enhanced antiviral immunity. Cell Biomater. 100180 (2025).
Kalantari, E. et al. Increased expression of ALDH1A1 in prostate cancer is correlated with tumor aggressiveness: a tissue microarray study of Iranian patients. Appl Immunohistochem. Mol. Morphol. 25, 592–598 (2017).
Wang, G., Wang, Z., Sarkar, F. H. & Wei, W. J. D. M. Targeting prostate cancer stem cells for cancer therapy. Discov Med. 13, 135 (2012).
Kalantari, E. et al. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Int J Exp Pathol. 100, 123–132 (2019).
Cai, H. H. & Pandit, A. J. C. R. I. Therapeutic monoclonal antibodies approved by FDA in 2020. Acta Scientific Microbiology. 4, 1–2 (2021).
Khalili, N., Keshavarz-Fathi, M., Shahkarami, S., Hirbod-Mobarakeh, A. & Rezaei N. J. J. O. O. P. P. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: a systematic review. Journal of Oncology Pharmacy Practice. 25, 903–917 (2019).
Butterfield, L. H. & Najjar, Y. G. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol. 24, 399–416 (2024).
Xie, G. L., Zhong, Z. H., Ye, T. W. & Xiao, Z. Q. Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review. BMC Surg. 25, 47 (2025).
Wojtukiewicz, M. Z. et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 40, 949–982 (2021).
White, J. M., Escorcia, F. E. & Viola, N. T. J. T. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics. 11, 6293–6314 (2021).
Lewis, C. D. et al. Targeting a radiosensitizing antibody-drug conjugate to a radiation-inducible antigen. Clin. Cancer Res. 27, 3224–3233 (2021).
López-Abad, A. et al. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. Prostate Int. 12, 20–26 (2024).
Sordo-Bahamonde, C. et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers. 15, 2912 (2023).
Fujimura, T., Takayama, K., Takahashi, S. & Inoue, S. Estrogen and androgen blockade for advanced prostate cancer in the era of precision medicine. Cancers. 10, 29 (2018).
Jiang, M. et al. Alterations of DNA damage repair in cancer: from mechanisms to applications. Ann. Transl. Med. 8, 1685 (2020).
Chen, A. PARP inhibitors: its role in treatment of cancer. Chin. J. Cancer 30, 463–471 (2011).
Morrissey, K. M., Yuraszeck, T. M., Li, C. C., Zhang, Y. & Kasichayanula, S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin. Transl. Sci. 9, 89–104 (2016).
Datta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S. & Jain, R. K. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educ. 39, 165–174 (2019).
Kartikasari, A. E. R. et al. Therapeutic cancer vaccines-T cell responses and epigenetic modulation. Front. Immunol. 9, 3109 (2018).
Vishweshwaraiah, Y. L. & Dokholyan N. V. J. F. I. I. mRNA vaccines for cancer immunotherapy. Front Immunol. 13, 1029069 (2022).
Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).
Buonaguro, L. & Tagliamonte, M. Peptide-based vaccine for cancer therapies. Front. Immunol. 14, 1210044 (2023).
Zhao, L., Zhang, M. & Cong, H. Advances in the study of HLA-restricted epitope vaccines. Hum. Vaccin Immunother. 9, 2566–2577 (2013).
Liao, H. C. & Liu, S. J. Advances in nucleic acid-based cancer vaccines. J. Biomed. Sci. 32, 10 (2025).
Sheykhhasan, M. et al. Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Biomed. Pharmacother. 184, 117858 (2025).
Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).
Leitner, W. W., Ying, H. & Restifo, N. P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18, 765–777 (1999).
Travieso, T., Li, J., Mahesh, S., Mello, J. & Blasi, M. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75 (2022).
Li, X. et al. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol. Med. 21, 274–311 (2023).
Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).
Li, Y. et al. Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines. Biomed. Pharmacother. 184, 117897 (2025).
Sipos, D. et al. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers. 17, 146 (2025).
Afrashteh, F., Simin, S. & Rezaei, N. The therapeutic effect of mRNA vaccines in glioma: a comprehensive review. Expert Rev. Clin. Immunol. 21, 603-615 (2025).
Nair, S. K. et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235, 540–549 (2002).
Wang, F., Kream, R. M. & Stefano, G. B. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med. Sci. Monit. 26, e924700–e924701 (2020).
Mead, M. N. et al. COVID-19 mRNA vaccines: lessons learned from the Registrational Trials and Global Vaccination Campaign. Cureus 16, e52876 (2024).
Amanpour, S. The rapid development and early success of COVID-19 vaccines have raised hopes for accelerating the cancer treatment mechanism. 76, 1 (2021).
Wang, X. et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors. Cell Res. 34, 661–664 (2024).
Zhang, T. Y. et al. Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: a meta-analysis. MedComm. 4, e286 (2023).
Vidhyalakshmi, R., Rajaganapathy, K., Kowsika, M. & Pratheeba, G. The transformative potential of mRNA vaccines in revolutionizing vaccine development and therapeutic applications. J. Pharma Insights Res. 2, 080–087 (2024).
Chakraborty, C., Sharma, A. R., Bhattacharya, M. & Lee, S.-S. From COVID-19 to cancer mRNA vaccines: moving from bench to clinic in the vaccine landscape. Front. Immunol. 12, 679344 (2021).
Gómez-Aguado, I. et al. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials 10, 364 (2020).
Chandra, S., Wilson, J. C., Good, D. & Wei, M. Q. mRNA vaccines: a new era in vaccine development. Oncol. Res. 32, 1543 (2024).
Jahanafrooz, Z. et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov. Today 25, 552–560 (2020).
Al Fayez, N. et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics 15, 1972 (2023).
Fu, Q. et al. mRNA vaccines in the context of cancer treatment: from concept to application. J. Transl. Med. 23, 12 (2025).
Mohite, P. et al. Revolutionizing cancer treatment: unleashing the power of viral vaccines, monoclonal antibodies, and proteolysis-targeting chimeras in the new era of immunotherapy. ACS Omega 9, 7277–7295 (2024).
Cheng, F. et al. Research advances on the stability of mRNA vaccines. Viruses 15, 668 (2023).
Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).
Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).
Michel, Y. M., Poncet, D., Piron, M., Kean, K. M. & Borman, A. M. Cap-Poly(A) synergy in mammalian cell-free extracts: investigation of the requirements for poly(A)-mediated stimulation of translation initiation*. J. Biol. Chem. 275, 32268–32276 (2000).
Passmore, L. A. & Coller, J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat. Rev. Mol. Cell Biol. 23, 93–106 (2022).
Steri, M., Idda, M. L., Whalen, M. B. & Orrù, V. Genetic variants in mRNA untranslated regions. Wiley Interdiscip. Rev. RNA 9, e1474 (2018).
Khalvandi, A. et al. Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis. World J. Urol. 39, 1831–1843 (2021).
Hinnebusch, A. G., Ivanov, I. P. & Sonenberg, N. Translational control by 5’-untranslated regions of eukaryotic mRNAs. Science 352, 1413–1416 (2016).
Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T. & Heidenreich, R. RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol. Biol. 1499, 89–107 (2017).
Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target Ther. 8, 450 (2023).
Buonaguro, L. & Tagliamonte, M. Selecting target antigens for cancer vaccine development. Vaccines. 8, 615 (2020).
Kiessling, A. et al. Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 4, 193–217 (2012).
Lin, G. et al. Key considerations for a prostate cancer mRNA vaccine. Crit. Rev. Oncol./Hematol. 208, 104643 (2025).
Wang, J. et al. Reversing the “cold” tumor microenvironment: the role of neoantigen vaccines in prostate cancer. J. Transl. Med. 23, 835 (2025).
Gao, Y. et al. Identification of neoantigens and construction of immune subtypes in prostate adenocarcinoma. Front. Genet. 13, 886983 (2022).
Ma, C. Q. et al. Crohn’s disease-associated ATG16L1 T300A genotype is associated with improved survival in gastric cancer. eBioMedicine. 25, 67 (2021).
Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. The dawn of mRNA vaccines: the COVID-19 case. J. Control. Release 333, 511–520 (2021).
Wang, F., Li, Z., Feng, X., Yang, D. & Lin, M. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 25, 11–26 (2022).
Mulroney, T. E. et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature 625, 189–194 (2024).
Chen, H. et al. Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer. Oncol. Lett. 21, 90 (2021).
Li, J. et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol. Cancer 22, 141 (2023).
Mitra, D. et al. Evolution of bioinformatics and its impact on modern bio-science in the twenty-first century: Special attention to pharmacology, plant science and drug discovery. Comput. Toxicol. 24, 100248 (2022).
Zheng, X. et al. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Mol. Cancer 20, 160 (2021).
Yu, M. Z., Wang, N. N., Zhu, J. Q. & Lin, Y. X. The clinical progress and challenges of mRNA vaccines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 15, e1894 (2023).
Zeng, D. et al. Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer. Adv. Sci. 12, e2417593 (2025).
Lu, B. et al. Advances in sequencing and omics studies in prostate cancer: unveiling molecular pathogenesis and clinical applications. Front. Oncol. 14, 1355551 (2024).
Gulley, J. L. et al. Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm. Oncoimmunology 5, e1107698 (2016).
Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010–26.e11 (2022).
Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–62.e24 (2020).
Tsao, S. Y. Potential of mRNA vaccines to become versatile cancer vaccines. World J. Clin. Oncol. 13, 663–674 (2022).
Peng, M. et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol. Cancer 18, 128 (2019).
Yuan, Y., Gao, F., Chang, Y., Zhao, Q. & He, X. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. Biomark. Res. 11, 6 (2023).
Li, M., Jiang, Y., Zhang, Y. & Zhu, H. Medical image analysis using deep learning algorithms. Front. Public Health 11, 1273253 (2023).
Lilleby, W. et al. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol. Immunother. 66, 891–901 (2017).
Liebl, M. C. & Hofmann, T. G. The role of p53 signaling in colorectal cancer. Cancers 13, 2125 (2021).
Imani, S., Tagit, O. & Pichon, C. Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact. npj Vaccines 9, 14 (2024).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).
Swetha, K. et al. Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. Vaccines 11, 658 (2023).
Huang, J., Yuen, D., Mintern, J. D. & Johnston, A. P. R. Opportunities for innovation: building on the success of lipid nanoparticle vaccines. Curr. Opin. Colloid Interface Sci. 55, 101468 (2021).
Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021).
Gao, Y., Yang, L., Li, Z., Peng, X. & Li, H. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends. Biomark. Res. 12, 93 (2024).
Caron, E. et al. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. Mol. Cell Proteom. 14, 3105–3117 (2015).
Laila, U. E., An, W. & Xu, Z.-.X. J. F. I. I. Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy. Front Immunol. 15, 1448489 (2024).
Ghosh, A. & Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 91, 528–539 (2004).
Yang, X. et al. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications. Expert Rev. Anticancer Ther. 14, 31–37 (2014).
Xu, M. et al. STEAP1–4 (six-transmembrane epithelial antigen of the prostate 1–4) and their clinical implications for prostate cancer. Cancers 14, 4034 (2022).
Kong, H. Y. & Byun, J. Emerging roles of human prostatic acid phosphatase. Biomol. Ther. 21, 10–20 (2013).
Epstein, J. I. PSA and PAP as immunohistochemical markers in prostate cancer. Urol. Clin. N. Am. 20, 757–770 (1993).
Pang, Z. et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 11, 104 (2023).
Mahony, T. J., Briody, T. E. & Ommeh S. C. Can the revolution in mRNA-based vaccine technologies solve the intractable health issues of current ruminant production systems? Vaccines. 12, 152 (2024).
Xu, G., Peng, H., Yao, R., Yang, Y. & Li, B. J. TFEB and TFE3 cooperate in regulating inorganic arsenic-induced autophagy-lysosome impairment and immuno-dysfunction in primary dendritic cells. Cell Biol. Toxicol. 40, 4 (2024).
Lee, J., Woodruff, M. C., Kim, E. H. & Nam, J.-H. Knife’s edge: balancing immunogenicity and reactogenicity in mRNA vaccines. Exp. Mol. Med. 55, 1305–1313 (2023).
Cao, Q., Fang, H. & Tian, H. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. Biomaterials 310, 122628 (2024).
Murat, P. & Tellam, J. Effects of messenger RNA structure and other translational control mechanisms on major histocompatibility complex-I mediated antigen presentation. Wiley Interdiscip. Rev. 6, 157–171 (2015).
Mohsenzadegan, M. et al. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. Biomark. Med. 9, 391–401 (2015).
Lu, R.-M. et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J. Biomed. Sci. 31, 89 (2024).
Ni, L. Advances in mRNA-based cancer vaccines. Vaccines. 11, 1599 (2023).
Yaremenko, A. V., Khan, M. M., Zhen, X., Tang, Y. & Tao, W. Clinical advances of mRNA vaccines for cancer immunotherapy. Med 6, 100562 (2025).
Karam, M. & Daoud, G. mRNA vaccines: past, present, future. Asian J. Pharm. Sci. 17, 491–522 (2022).
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Thomas, S. & Prendergast, G. C. Cancer vaccines: a brief overview. Methods Mol. Biol. 1403, 755–761 (2016).
Grimmett, E. et al. Cancer vaccines: past, present and future; a review article. Discov. Oncol. 13, 31 (2022).
Schumacher, T. N., Scheper, W. & Kvistborg, P. J. A. R. O. I. Cancer Neoantigens 37, 173–200 (2019).
Fu, C. & Jiang, A. Dendritic cells CD8 T cell Immunity in tumor microenvironment. 9, 3059 (2018).
Apavaloaei, A., Hardy, M.-P., Thibault, P. & Perreault, C. J. C. The origin and immune recognition of tumor-specific antigens. Cancers (Basel). 12, 2607 (2020).
Tjoa, B. et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28, 65–69 (1996).
Heiser, A. et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166, 2953–2960 (2001).
DiPaola, R. S. et al. A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer. J. Transl. Med. 4, 1–5 (2006).
Bolhassani, A., Naderi, N. & Soleymani, S. Prospects and progress of Listeria-based cancer vaccines. Expert Opin. Biol. Ther. 17, 1389–1400 (2017).
Haas, N. B. et al. Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. J. Immunother. Cancer 3, 1–2 (2015).
Gulley, J. L. et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 1051–1061 (2019).
Hodge, J. W., McLaughlin, J. P., Kantor, J. A. & Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15, 759–768 (1997).
Johnson, L. E., Frye, T. P., Chinnasamy, N., Chinnasamy, D. & McNeel, D. G. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol. Immunother. 56, 885–895 (2007).
Autio K. A. et al. First-in-human, Phase I Study of PF-06753512, A Vaccine-based Immunotherapy Regimen (PrCa VBIR), in Biochemical Relapse (BCR) and Metastatic Castration-resistant Prostate Cancer (mCRPC). (Wolters Kluwer Health, 2021).
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients with Castration-resistant, Metastatic Prostate Cancer. https://clinicaltrials.gov/study/NCT04090528 (2019).
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).
Wang, H. et al. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. Emerg. Microbes Infect. 11, 1550–1553 (2022).
Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014).
Madan, R. A. et al. Putting the pieces together: completing the mechanism of action jigsaw for sipuleucel-T. J. Natl. Cancer Inst. 112, 562–573 (2020).
Simons, J. W. & editors. Granulocyte-macrophage colony-stimulating factor− transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer. Urol. Oncol. 24, 419-424 (2006).
Drake, C. G. Immunotherapy for prostate cancer: walk, don’t run. Am. Soc. Clin. Oncol. 27, 4035–4037 (2009).
Stenzl, A. et al. Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol. 28, v408–v409 (2017).
Podrazil, M. et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6, 18192 (2015).
An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer [Internet]. https://clinicaltrials.gov/study/NCT02140138 (2014).
Umscheid, C. A., Margolis, D. J. & Grossman, C. E. Key concepts of clinical trials: a narrative review. Postgrad. Med. 123, 194–204 (2011).
Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target Ther. 7, 166 (2022).
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018).
Kouiavskaia, D. V. et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J. Immunother. 32, 655–666 (2009).
McNeel, D. G. et al. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J. Clin. Immunol. 23, 62–72 (2003).
Xiang, W., Yu, L., Chen, X. & Herold, M. J. Artificial intelligence in cancer immunotherapy: navigating challenges and unlocking opportunities. Engineering. 44, 12–16 (2024).
Nalla, L. V., Kanukolanu, A., Yeduvaka, M. & Gajula, S. N. R. Advancements in single-cell proteomics and mass spectrometry-based techniques for unmasking cellular diversity in triple negative breast cancer. Proteom. Clin. Appl. 19, e202400101 (2025).
Mienye, D. & Swart, T. A comprehensive review of deep learning: architectures, recent advances, and applications. Information 15, 755 (2024).
Olawade, D. B. et al. Leveraging artificial intelligence in vaccine development: a narrative review. J. Microbiol. Methods 224, 106998 (2024).
Imani, S. et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front. Cell. Infect. Microbiol. 14, 1501010 (2025).
Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).
Jin, L., Zhou, Y., Zhang, S. & Chen, S.-J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J. Biol. Chem. 301, 108015 (2025).
Islam, R., Imran, A. & Rabbi, M. F. Prostate cancer detection from MRI using efficient feature extraction with transfer learning. Prostate Cancer 2024, 1588891 (2024).
Chi, W.-Y. et al. Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens. J. Biomed. Sci. 31, 94 (2024).
Kumar, A., Dixit, S., Srinivasan, K. & Vincent, P. M. D. Personalized cancer vaccine design using AI-powered technologies. Front. Immunol. 15, 1357217 (2024).
Lloren, K. K. S., Senevirathne, A. & Lee, J. H. Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria. Mater. Today Bio 29, 101349 (2024).
Bezbaruah, R. et al. Nanoparticle-based delivery systems for vaccines. Vaccines 10, 1946 (2022).
Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).
Wang, W. et al. Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. Acta Pharm. Sin. B 12, 2950–2962 (2022).
Hu, C. & Dignam, J. J. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis. Oncol. 3, 24 (2019).
Valdespino, V., Tsagozis, P. & Pisa, P. Current perspectives in the treatment of advanced prostate cancer. Med. Oncol. 24, 273–286 (2007).
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
Bidram, M. et al. mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients. Vaccines (Basel). 9, 1060 (2021).
Kreiter, S., Diken, M., Selmi, A., Türeci, Ö & Sahin, U. J. C. O. I. I. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr. Opin. Immunol. 23, 399–406 (2011).
Tang, Y., Yi, X. & Ai, J. mRNA vaccines for prostate cancer: a novel promising immunotherapy. Biochim. Biophys. Acta Rev. Cancer. 1880, 189333 (2025).
Liu, Y. et al. Development of mRNA lipid nanoparticles: targeting and therapeutic aspects. Int. J. Mol. Sci. 25, 18 (2024).
Park, S. J., Saito-Adachi, M., Komiyama, Y. & Nakai, K. Advances, practice, and clinical perspectives in high-throughput sequencing. Oral. Dis. 22, 353–364 (2016).
Van Poppel, H. et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat. Rev. Urol. 19, 562–572 (2022).
Faskhoudi, M. A. et al. Molecular landscape of c-Myc signaling in prostate cancer: a roadmap to clinical translation. Pathol. Res. Pract. 233, 153851 (2022).
Bourdon, J.-C. p53 and its isoforms in cancer. Br. J. Cancer 97, 277–282 (2007).
Teroerde, M, et al. Revisiting the Role of p53 in Prostate Cancer. In: Bott SRJ, Ng KL, editors. Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; Chapter 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK571319/, https://doi.org/10.36255/exonpublications.prostatecancer.p53.2021 (2021).
Strawbridge, R. J., Nistér, M., Brismar, K., Grönberg, H. & Li, C. MUC1 as a putative prognostic marker for prostate cancer. Biomarker Insights 3, BMI. S666 (2008).
Phin, S., Moore, M. & Cotter, P. D. Genomic rearrangements of PTEN in prostate cancer. Front. Oncol. 3, 2013 (2013).
Pedrani, M. et al. Prognostic and predictive role of SPOP Mutations in prostate cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 7, 1199–1215 (2024).
Kalantari, E. et al. Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res. 23, 793–802 (2017).
Rausch, S., Schwentner, C., Stenzl, A. & Bedke, J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum. Vaccin Immunother. 10, 3146–3152 (2014).
Li, Y. J. et al. High stoichiometry phosphorylation of talin at T144/T150 or S446 produces contrasting effects on calpain-mediated talin cleavage and cell migration. J. Cancer 7, 1645–1652 (2016).
Koch, S. D. et al. A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. J. Immunother. Cancer 2, P85 (2014).
Su, Z. et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798–3807 (2005).
Schuhmacher, J. et al. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J. Immunother. Cancer 8, e001157 (2020).